Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633984 · ClinicalTrials.gov registry record · Phase 4
D-Cycloserine Enhancement of Exposure in Social Phobia
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 169
- Enrollment target
NCT00633984: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00633984 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633984, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of this study is to test a drug called d-cycloserine to see if it can help people with a condition called social phobia. Social phobia is also called "social anxiety disorder." Social phobia is a constant fear of social or performance situations. Social situations include group gatherings of any kind. Performance situations might include times when a person would have to do something in public, such as speak up in class or at a meeting. A person with this condition worries about being embarrassed, or about other people's opinions. People with social phobia usually feel extremely anxious (nervous and worried) about being the focus of attention. They often avoid social and performance situations. This behavior can have a negative effect on the quality of their lives and relationships. In this study, we want to find out if d-cycloserine can help control social phobia when the drug is added to the standard treatment for this condition. The standard treatment is cognitive-behavior therapy (CBT). CBT is a form of talk therapy involving discussion with a therapist, along with practicing the feelings or events that the person finds frightening.
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Behavioral Group Therapy (CBGT)
- DRUG D-Cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633984
The ClinicalTrials.gov registry entry for NCT00633984 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00633984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633984 about?
NCT00633984 is a clinical study titled "D-Cycloserine Enhancement of Exposure in Social Phobia". The purpose of this study is to test a drug called d-cycloserine to see if it can help people with a condition called social phobia. Social phobia is also called "social anxiety disorder." Social phobia is a constant fear of social or performance situations. Social situations include group gathering...
What is the current status of trial NCT00633984?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 169 participants. The study started on 2007-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00633984?
The interventions under investigation include: Placebo (DRUG), Cognitive Behavioral Group Therapy (CBGT) (BEHAVIORAL), D-Cycloserine (DRUG).
Who is sponsoring clinical trial NCT00633984?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.